COVID-19 vacine targeting SARS-CoV-2 spike protein RBD (Monash Institute of Pharmaceutical Sciences/Burnet Institute)

N/A

Report date: 2025/10/28 17:51:08

Base Information

Drug NameCOVID-19 vacine targeting SARS-CoV-2 spike protein RBD (Monash Institute of Pharmaceutical Sciences/Burnet Institute)
Drug Alias NameSARS-CoV-2 vaccine (Monash Institute of Pharmaceutical Sciences)mRNA vaccine (omicron variant) (Monash Institute of Pharmaceutical Sciences)
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionCoronavirus spike glycoprotein modulators
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMonash Institute of Pharmaceutical Sciences
China Registration ClassN/A

Develop Information

Active CompaniesMonash Institute of Pharmaceutical SciencesThe Macfarlane Burnet Institute For Medical Research And Public Health Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A